Mallinckrodt Initiates Rolling Submission of New Drug Application to the FDA for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1, Expects Complete New Drug Application Submission Within Coming Months
Benzinga Newsdesk